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Abstract.
Background: Cognitive functions and activities of daily living (ADL) become increasingly impaired with progressing
Alzheimer’s disease. However, the temporal dynamics of this decline are inconsistent.
Objective: To gain insight into the classical temporal cascade of specific cognitive and ADL changes, which may aid in
improving detection of an impending clinical deterioration in patients, and to select ADL items and tests most sensitive to
change in a specific disease stage.
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Methods: Patients with mild Alzheimer’s dementia (AD; MMSE = 23.9 ± 2.88) were followed at 12 and 24 months. Lead-
lag analysis of changes in cognitive and functional outcome measures (CDR-SOB, 12 neuropsychological subtest scores
from the CERAD + test battery, 25 Bayer-ADL items) was applied to rank the temporal sequence of changes on an ordinal
scale.
Results: Of 164 patients with mild AD, moderate disease progression was identified in 84 patients over 24 months (MMSE
5.8 ± 8.64; CDR-SOB 4.32 ± 4.03). Ten Bayer-ADL item measures were altered early in moderate progressors and included
in a new ADL composite score. Accordingly, the new ADL score surpassed all neuropsychological measures in repeated
lead-lag analysis. The Bayer-ADL total score, TMT-A, and MMSE were lagging variables in all lead-lag analyses.
Conclusion: Short-term clinical deterioration in mild AD is initially preceded by changes (i.e., decline) in a well-defined set
of ADL and not in classical cognitive measures.
Keywords: Alzheimer’s disease, bayer activities of daily living scale, cognitive changes, disease progression, functional
changes, lead and lag analysis
INTRODUCTION
Progressive cognitive and functional decline
over the disease course is the main hallmark of
Alzheimer’s disease [1]. However, activities of daily
living (ADL) and cognitive tests show different
rates of change along the Alzheimer’s continuum
[2, 3]. Time-saving and easy to apply instruments,
whose longitudinal changes precede a cascade of
changes in other neuropsychological instruments and
consequent pronounced clinical deterioration, are
essential for planning appropriate pharmacological
and psychosocial interventions. Timely implementa-
tion of such measures might compensate, maintain,
or enhance neuropsychological abilities, improve
the quality of life of both patients and caregivers
by reducing distress, depression, and psychological
morbidity, facilitate planning of subsequent care, per-
sonal, financial and health-related decision-making,
and delay nursing home admission of patients
[4–6]. Although most studies monitoring longitudinal
changes focused on the Mini-Mental State Exam-
ination (MMSE) [3, 7–11], the Clinical Dementia
Rating-Sum of Boxes (CDR-SOB) [3, 9, 12], and
the Alzheimer’s Disease Assessment Scale-cognitive
subscale (ADAS-Cog) [3, 8, 9, 11, 13, 14], the
most optimal instrument reflecting longitudinal dis-
ease progression in mild dementia of Alzheimer-type
remains elusive [9]. In this framework, the hierarchy
of functional loss measured by changes in ADL has
been generally relegated to the background. However,
as ADL are sustained by multiple cognitive domains,
they could consequently be even more vulnerable
to imminent marked clinical deterioration than clas-
sical cognitive instruments. Based on this concept,
Reppermund and colleagues [15, 16] conducted two
predictive studies based on the Bayer-ADL (B-ADL)
scale. The B-ADL is a 25 item, informant-based
instrument developed to assess functional disabili-
ties in the early stages of dementia [17]. Unlike the
Alzheimer’s Disease Cooperative Study ADL scale
[18], which is more time-consuming and requires
an interviewer, the B-ADL is a time-saving ques-
tionnaire that is usually completed by the primary
caregiver. Reppermund and colleagues divided the B-
ADL into high and low cognitive demanding items.
Difficulties in highly cognitive demanding activities
at baseline were identified as an early marker of both
progression to mild cognitive impairment (MCI) and
dementia at 24-month follow-up [16].
In the present study, a new approach was applied
by performing lead-lag analysis of changes in B-
ADL items and subscales, including those described
by Reppermund and colleagues [15, 16]), as well as
classical cognitive measures in a sample of patients
with mild Alzheimer’s disease dementia (AD) over
24 months. Lead-lag analysis identifies items that
either precede (“lead”) or follow (“lag”) that of other
items in capturing change over time. To make our
analysis comprehensible, one could compare this to
a road bicycle race. Most cyclists pedal at a similar
and constant speed; however, one cyclist frequently
detaches from the group. In some cases, the sprinter
generates a large distance to the remainder of the
group, which maintains a constant speed. However,
in other cases, the sprinter causes the speed of the
group to increase as the remainder desire to catch up
with the leader. Accordingly, the sprinter here rep-
resents an early marker of the acceleration of the
group. As there is no gold standard for assessing
disease progression in the early stages of AD, we
aimed to identify alterations in a functional or cogni-
tive measure preceding a cascade of changes in other
neuropsychological variables (the “group” catching
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up with the “sprinter”), and, accordingly, imminent
marked clinical deterioration.
METHODS
Participants
Patients from the long-term diagnostic and prog-
nostic study (DAP study) as part of the German
Dementia Competence Network (DCN) observa-
tional cohort with a mild dementia syndrome
at baseline, etiologically classified as due to
Alzheimer’s disease, were included in the study
(n = 164). Inclusion criteria were the collection of
outcome measures at baseline and two annual follow-
ups. Diagnostic criteria for AD and study procedures
have been described in detail elsewhere [19]. The
DCN study was approved by the local ethics com-
mittees at each center, and conducted in accordance
with the Declaration of Helsinki.
B-ADL questionnaire to detect functional
impairment
Functional decline was assessed by the B-ADL,
whereby a cumulative score is obtained that rates
impairment severity. The B-ADL covers a wide range
of ADL with the majority of items relating to com-
plex, instrumental tasks. All items were selected for
their sensitivity to cognitive impairment, simplic-
ity of the concept, international applicability, and
relevance to patients coping with the demands of
everyday life [17]. The B-ADL instrument is suit-
able for both cross-sectional screening as well as
longitudinal follow-up to monitor clinical deteriora-
tion within the Alzheimer’s disease continuum [17].
The following items constituted the applied ques-
tionnaire: 1) appliances: using domestic appliances;
2) care: self-care; 3) continuation: task persistence
following a brief interruption; 4) conversation: partic-
ipation; 5) cooking: ability to prepare food; 6) dates:
observing important dates or events; 7) describing:
outlining what was observed or heard; 8) directions:
ability to provide directions upon questioning; 9)
everyday: managing daily activities; 10) finances:
understanding personal financial affairs; 11) hygiene:
personal hygiene; 12) leisure: participating in leisure
activities; 13) medication: self-medication; 14) mes-
sage: taking a message for another individual; 15)
money: correct counting; 16) orientation: finding the
way in an unfamiliar setting; 17) parallel act.: syn-
chronous task management; 18) pressure: performing
a task under pressure; 19) reading: concentration;
20) safety: taking precaution; 21) shopping: ability
to purchase items; 22) telephone: ability to use; 23)
transportation: ability to use; 24) unfamiliar situa-
tion: coping with unknown circumstances; and 25)
walking: taking a walk without getting lost.
Application and scoring of the B-ADL scale
The following paragraph is extracted from the
original manuscript of Hindmarch and colleagues
describing the application and scoring of the B-ADL
scale [17]:
“The relative or caregiver assessing the patient’s
difficulties with ADLs using the B-ADL is
instructed to indicate how often difficulties occur
with the activity in question by drawing a line
through one of the circles numbered ‘1’ to ‘10’.
Additionally, a ‘not applicable’ category is pro-
vided for instances where a question is not
appropriate or relevant to a given patient. Only
when a choice cannot be reasonably made is the
informant asked to tick the box ‘unknown’. To
compute a global scale score, first the individ-
ual item scores are summed up. Items rated ‘not
applicable’ and ‘unknown’ are not used for the
computation of this sum score. The total is then
divided by the number of items rated between ‘1’
and ‘10’. Thus, the scale’s sum score is corrected
for the number of irrelevant items and missing
scores. The resulting figure is rounded to two
decimal places, ensuring that total scores of the
B-ADL range between values 1.00 and 10.00”
[17].
Neuropsychological tests and scales to detect
cognitive and functional impairment
Dementia severity was assessed via the CDR-
SOB [20]. The CDR-SOB is a summed total score
of ratings across six domains (memory, orientation,
judgment and problem solving, community affairs,
home, and hobbies, and personal care), with scores
ranging from 0 to 18 [21]. Impairment is defined only
when caused by cognitive loss rather than by a phys-
ical disability or other non-cognitive factors [22].
This instrument is used to assess disease progression
and frequently utilized as a primary efficacy endpoint
[23]. Global cognitive functioning was assessed using
a standardized, neuropsychological test battery pub-
lished by the Consortium to Establish a Registry for
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Alzheimer’s Disease (CERAD; [24]), supplemented
by the Wechsler Memory Scale – Revised (WMS-
R) immediate and delayed logical memory [25]), the
Mini-Mental State Examination (MMSE) [26]) and
the Clock Drawing Test (CDT; [27]). The CERAD
comprised the following subtests: 1) BNT-15 = 15-
Item Version of the Boston Naming Test; 2) Semantic
fluency (animals) 3) Word list (immediate recall);
4) Word list (immediate recall, intrusions); 5) Word
list (delayed recall); 6) Word list (delayed recall,
intrusions); 7) Word list (recognition task, correct
inclusions); 8) Word list (recognition task, correct
rejections); 9) Figure constructional praxia (copy);
10) Figure constructional praxia (delayed recall); 11)
TMT-A = Trail Making Test A; 12) TMT-B = Trail
Making Test B. There were insufficient data for the
TMT-B to generate comparisons, as most patients
reached the time ceiling (5 min) and showed a floor
effect. Accordingly, the TMT-B was not included in
further analyses.
Definition of collective
Lead and lag relationships have been investigated
in biological, computational, and social sciences
(e.g., [28, 29]). Since we intended to identify func-
tional and cognitive measures changing early in
short-term, marked disease progression and lead-
lag analyses methodologically required a sufficient
dynamic of change to ensure the significance of the
results, patients with a deterioration of CDR-SOB
≥2 within 24 months were identified for analyses.
Although most authors have defined a mean individ-
ual annual increase between 1.28 and 1.91 points,
there remains a lack of general consensus regarding
the rate of progression of the CDR-SOB score in mild
AD [21, 30–32].
Imputation
Lead-lag analyses were based on participants who
fulfilled the eligibility criteria and all outcome assess-
ments at all visits. For each patient, missing values
of 10% were permitted. Rates of missing data in
longitudinal research vary from 5 to 20%, although
the acceptable consensus among most researchers is
10% [33–34]. Patients exceeding the applied value
were excluded. Missing values were imputed using
the Multivariate Imputations by Chained Equations
(MICE) algorithm, with predictive mean matching
provided by R-package mice version 2.3.0 (R-version
3.4.0) [35]. Differences in mean values ± standard
deviations between groups were evaluated with Stu-
dent’s t-test or Welch’s unequal variances t-test after
the F-test of equality of variances.
Lead and lag analysis
To identify and rank-order on an ordinal scale,
changes in functional and cognitive measures preced-
ing a cascade of changes in other neuropsychological
variables, and accordingly imminent marked clinical
deterioration, two lead-lag analyses were conducted
sequentially. In the first analysis, functional changes
(i.e., decline) in individual B-ADL item measures
over 24 months (i.e., 12 and 24-month follow-ups)
were rank-ordered by median lead-lag coefficients.
Consequently, two composite scores comprising all
leading items with median lead-lag coefficients above
zero (B-ADL LEAD) and all lagging items with
median lead-lag coefficients below zero (B-ADL
LAG) were created. A high average lead-lag coef-
ficient indicated a leading variable for many patients.
Furthermore, a change in variables with high and
positive lead-lag median coefficients chronologically
preceded imminent marked clinical deterioration.
The first analysis intended to create a B-ADL LEAD
composite score for comparison in a further lead-lag
analysis with a set of classical cognitive measures.
Therefore, the aim of the second lead-lag analysis
was to explore whether the impending clinical dete-
rioration in mild AD is first preceded by changes in a
well-defined set of ADL items (i.e., B-ADL LEAD)
or classical cognitive measures (i.e., variables of the
CERAD+, WMS-R immediate and delayed logical
memory, MMSE, CDT, and CDR). The second lead-
lag analysis was performed as described for the first
lead-lag analysis.
Data discretization
To perform all lead-lag analyses, each functional
and cognitive variable was described by a profile
comprising three time points: baseline, first follow-
up, and second follow-up measurements. For noise
reduction, the change in the variables was subdivided
into five discrete categories, namely very low, low,
medium, high, and very high, according to the quin-
tiles of the complete variable distribution (20%, 40%,
60%, 80%, and 100%, respectively). Therefore, the
data of the variables were separated into five equal-
sized parts (20% quantiles). In addition to filtering
noise, the advantage of this transformation is based
on rendering the different variables comparable.
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Cross-correlation analyses
Cross-correlation is one of the most common met-
rics used to align time-series data [36]. To identify
whether one variable leads before another, standard
cross-correlation coefficients of the discretized pro-
files were calculated patient-wise and averaged for
all patients. Therefore, average lead-lag coefficients
were the result of cross-correlation of each variable
against all others. Variables were ordered by median
lead-lag coefficients. Details of cross-correlation
analyses can be found in the Supplementary Material.
Bootstrapping estimates
Lead-lag analyses were assessed by calculating
bootstrapping estimates. Bootstrapping was used to
estimate the internal validity. To perform resampling,
time-profiles of each patient were shuffled, fol-
lowed by reanalysis. Therefore, lead-lag coefficients
were recalculated for 1000 resampling replications.
For each variable, a normal distribution was fit-
ted to the corresponding resampling using median
lead-lag coefficients. The Shapiro-Wilk test was
used to determine the normality of the variables.
The estimated normal distribution was used to
calculate the p value of a given variable. The
Benjamini-Hochberg procedure was used to correct
for multiple testing. Significance is indicated by
an asterisk: *p value < 0.05; **p value < 0.01; and
***p value < 0.001. The null hypothesis was that
the median lead-lag coefficient was due to chance.
A significant p value indicated non-randomness. In
addition, a p value was calculated for the complete
lead-lag analysis. Therefore, the variance of the orig-
inal median lead-lag coefficients was compared with
the variance of 1000 resamples. A fitted normal
distribution using these 1000 resampled variances
(background distribution) was used to calculate the
p value for non-randomness.
Interpretation of the differences in medians for
lead-lag coefficients
Since our lead-lag analysis was customized espe-
cially for this study, we do not have a good
reference for interpreting the absolute values of the
median lead-lag coefficients. However, resampling
was applied to overcome this issue. This method pro-
vides a reference for what could be expected from
random data. A significant p value indicated non-
randomness. Therefore, in the current manuscript, we
Fig. 1. Study flow of dementia patients of the DAP study popu-
lation. AD, Alzheimer’s disease dementia; DAP, Diagnostic and
prognostic study.
did not assess the absolute values of the median lead-
lag coefficients but rather the ordering of the items.
Together with resampling, we are in the opinion that
this is the appropriate manner of interpreting results.
RESULTS
Patient characteristics
Of the 351 patients with mild AD from the DAP
cohort, 164 were eligible for the study (Fig. 1). Com-
plete outcome measures or <10% of missing values
at baseline, 12 months, and 24 months of follow-
up were available from these patients (Fig. 1). Of
the 164 patients with mild AD, clinical deteriora-
tion was identified in 86 patients, with a CDR-SOB
≥2 within 24 months ( MMSE 5.8 ± 8.64; 
CDR-SOB 4.32 ± 4.03). These patients were termed
moderate progressors and selected for subsequent
analyses. Demographic and clinical characteristics of
the subcohorts at baseline are depicted in Table 1
and Supplementary Table 1. Differences between
the study sample and the DAP study population
(AD patients only) were identified for several cog-
nitive and functional variables, however, not for
demographic variables (Table 1 and Supplementary
Table 1).
Some functional skills deteriorate early in
moderate progressors
Cross-correlation analysis results ranking B-ADL
items in leading and lagging clinical changes are
shown in Fig. 2. In the first lead-lag analysis,
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Table 1
Demographic and clinical characteristics at baseline
Slow AD Moderate AD p AD patients from p
progressors progressors the DAP study
n = 78 n = 86 n = 351
Age 69 (7.76) 72.3 (8.26) <0.05 72.8 (8.30) 0.59
Female % 57.69% 47.67% 0.27 45.46 % 0.99
Education (y) 9.06 (1.96) 9.45 (1.92) 0.27 9.23 (1.98) 1
MMSE 24.6 (2.49) 23.3 (3.09) <0.01 22.7 (3.25) <0.05
CDR (SOB) 4.53 (1.35) 4.32 (1.37) 0.39 4.87 (1.57) 0.14
CDT 2.53 (1.12) 2.76 (1.15) 0.27 3.03 (1.18) 0.09
B-ADL (TS) 3.76 (1.69) 3.96 (2.09) 0.57 4.64 (2.10) <0.05
AD, Alzheimer’s disease dementia; B-ADL (TS), Bayer-activities of daily living (total score); CDR (SOB),
Clinical Dementia Rating Scale (sum of boxes); CDT, Clock Drawing Test; DAP, Diagnostic and prognostic
study; MMSE, Mini-Mental State Examination; y, years.
Fig. 2. Box plots of average lead-lag coefficients comprising individual B-ADL items: moderate AD progressors. Each box is composed of
24 values. Items are ordered by median lead-lag coefficients. A change in items with positive and high lead-lag coefficients occurs earlier
in moderate AD progressors. p values were calculated with resampling. Using a bootstrapping estimate, the p value for complete lead-lag
analysis was <0.001. Appliances, using domestic appliances; care, self-care; continuation, task persistence following a brief interruption;
conversation, participation; cooking, ability to prepare food; dates, observing important dates or events; describing, outlining what was
observed or heard; directions, ability to provide directions upon questioning; everyday, managing daily activities; finances, understanding
personal financial affairs; hygiene, personal hygiene; leisure, participating in leisure activities; medication, self-medication; message, taking
a message for another individual; money, correct counting; orientation, finding the way in an unfamiliar setting; parallel act., synchronous
task management; pressure, performing a task under pressure; reading, concentration; safety, taking precaution; shopping, ability to purchase
items; telephone, ability to use; transportation, ability to use; unfamiliar situation, coping with unknown circumstances; and walking, taking
a walk without getting lost.
changes (i.e., decline) in the four B-ADL items “par-
allel activities” (p < 0.001), “finances” (p < 0.001),
“orientation” (p < 0.01), and “cooking” (p < 0.05)
preceded all other B-ADL items. p values were
calculated with resampling. Additionally, the six
B-ADL items “unfamiliar situation”, “pressure”,
“medication”, “shopping”, “message”, and “dates”
had median lead-lag coefficients above zero (Fig. 2).
Using bootstrapping estimates, the p value for com-
plete lead-lag analysis was <0.001.
The 10 leading B-ADL items with median lead-
lag coefficients above zero were included in a
B-ADL composite score (B-ADL LEAD), whereas
the remaining 15 items were included in a second
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Fig. 3. Box plots of average lead-lag coefficients comprising the B-ADL (LEAD) and (LAG) composite scores, as well as cognitive variables:
moderate AD progressors. Each box is composed of 17 values. Variables are ordered by median lead-lag coefficients. A change in variables
with positive and high lead-lag coefficients occurs earlier in moderate AD progressors. p values were calculated with resampling. Using
a bootstrapping estimate, the p value for complete lead-lag analysis was 0.000892. B-ADL (LEAD), Bayer-activities of daily living (i.e.,
B-ADL items with median lead-lag coefficients >0); B-ADL (LAG), Bayer-activities of daily living (i.e., B-ADL items with median lead-lag
coefficients <0); C.BNT, CERAD. 15-Item Version of the Boston Naming Test; C. Fig (C), CERAD. Figure constructional praxia (copy); C.
Fig (DR), CERAD. Figure constructional praxia (delayed recall); C. SemF, CERAD. Semantic fluency (animals); C. Word(DR), CERAD.
Word list (delayed recall); C. Word (DR-I), CERAD. Word list (delayed recall, intrusions); C. Word (Inc), CERAD. Word list (recognition
task, correct inclusions); C. Word (IR), CERAD. Word list (immediate recall).; C. Word (IR-I), CERAD. Word list (immediate recall,
intrusions); C. Word (Rej), CERAD. Word list (recognition task, correct rejections); CDR (SB), Clinical Dementia Rating Scale (sum of
boxes); CDT, Clock Drawing Test; MMSE, Mini-Mental State Examination; TMT-A, Trail Making Test A; WLM (DR), Wechsler Memory
Scale-Revised (delayed recall, logical memory); WLM (IR), Wechsler Memory Scale-Revised (immediate recall, logical memory).
composite score (B-ADL LAG). Next, we analyzed
whether imminent marked clinical deterioration is
preceded by changes in the B-ADL LEAD composite
score or in classical cognitive tests.
Lead-lag analysis comprising classical cognitive
variables, as well as the B-ADL (LEAD) and (LAG)
composite scores, demonstrated the B-ADL (LEAD)
to be ranked first (p < 0.05), followed by TMT-A,
MMSE, WMS-R delayed logical memory, Word list
(delayed recall, intrusions), B-ADL (LAG), Semantic
fluency (animals), and Figure constructional praxia
(copy), which were not significant for all variables
(Fig. 3). Using bootstrapping estimates, the p value
for the complete lead-lag analysis was <0.01.
As the B-ADL measures (i.e., LEAD, LAG, total
score as well as the composite scores described by
Reppermund and colleagues [15, 16], namely high
cognitive demand and low cognitive demand) share
several individual items, their correlation could favor
individual median lead-lag coefficients and, there-
fore, leading positions in a general lead-lag analysis
comprising all B-ADL, as well as classical cognitive
measures. To prevent this effect and indirectly exam-
ine the consistency of our results, individual lead-lag
subanalyses were performed. The first subanalysis
included the B-ADL total score and all cognitive
variables (Supplementary Figure 1). The second sub-
analysis included the B-ADL high cognitive demand
factor, low cognitive demand factor, and all cognitive
variables (Supplementary Figure 2).
All lead-lag analyses comprising B-ADL and cog-
nitive variables showed similar results except for a
few subtle changes in the temporal order of sev-
eral measures. These variations were due to minimal
differences between several median lead-lag coef-
ficients. All B-ADL variables exhibited positive
median lead-lag coefficients and leading positions
for several variables. In the first subanalysis, the B-
ADL total score ranked first, followed by the TMT-A
and MMSE, with results not significant for all vari-
ables. Using bootstrapping estimates, the p value for
the complete lead-lag analysis was <0.05 (Supple-
mentary Figure 1). In the second subanalysis, the
B-ADL low cognitive demand factor ranked fourth,
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followed by Word list (delayed recall, intrusions)
and the B-ADL high cognitive demand factor. These
variables were preceded by the TMT-A, MMSE,
and Figure constructional praxia (copy), with all
variables not significant. Using bootstrapping esti-
mates, the p value for complete lead-lag analysis was
0.01 (Supplementary Figure 2). A comparison of the
results of all lead-lag analyses comprising B-ADL
and cognitive variables demonstrated the following
ranking: 1) B-ADL (LEAD), 2) B-ADL total score,
3) TMT-A, and 4) MMSE. Although the B-ADL
(LEAD) and the B-ADL total score are in the first
position (Fig. 3 and Supplementary Figure 1), the
median lead-lag coefficient of the B-ADL (LEAD)
is both significant and higher than that of the B-
ADL total score when compared to the respective
analyses of the remaining variables. The WMS-R
delayed logical memory, Word list (delayed recall,
intrusions), Semantic fluency (animals), and Figure
constructional praxia (copy) were among the lagging
variables in all lead-lag analyses, while the Fig-
ure constructional praxia (delayed recall) (p < 0.05;
Supplementary Figure 2), Word list (immediate
recall), Word list (recognition task, correct inclu-
sions), and CDT consistently demonstrated a lagging
position.
DISCUSSION
To the best of our knowledge, the present study
reports the first lead-lag analysis examining change
over time in instrumental ADL and standard cogni-
tive measures in mild AD. A cascade of changes in
items belonging to the B-ADL (LEAD) composite
score occurs earlier in moderate AD progressors than
changes in the B-ADL high cognitive demand factor
score, the B-ADL total score, and the cognitive test
scores examined. Therefore, we propose this subset
of B-ADL items as a highly targeted tool to detect
impending clinical deterioration in mild AD patients.
Moreover, after corroboration in an independent data
set, the B-ADL (LEAD) subscale could be imple-
mented as an outcome measure in intervention studies
instead of the overall B-ADL scale.
The indicative value for subsequent marked clin-
ical deterioration showed by the high cognitive
demand factor proposed by Reppermund and col-
leagues [15, 16] was found to be limited. Accordingly,
items such as ‘direction’, ‘continuation’, or ‘read-
ing’ were observed to be lagging in the analysis of
single B-ADL item measures. This result may be
due to two reasons. First, the analysis by Repper-
mund and co-workers was conducted on samples
comprising cognitively normal participants and MCI
patients. In contrast, the present study included indi-
viduals at an early stage of AD that demonstrated
far more functional deficits at the baseline evalua-
tion. Second, Reppermund and colleagues based their
analyses on predictions concerning deficit severity at
baseline rather than exploring the temporal sequence
of change in the high cognitive demand factor score
over time. Despite this finding and the clear leading
position exhibited by the B-ADL (LEAD) compos-
ite score, all other B-ADL measures, especially the
B-ADL total score, showed positive median lead-
lag coefficients. Collectively, these results support
the importance of analyzing longitudinal changes in
functional abilities over a short period as a reliable
measure preceding short-term, marked clinical dete-
rioration in mild AD.
Investigation of the temporal sequence of change
over time in single B-ADL items measures revealed
changes in instrumental activities with high exec-
utive functioning, processing speed, and memory
demand preceding subsequent short-term, marked
clinical deterioration. In contrast, a change in sev-
eral activities based on automatism or procedural
memory processes with low executive functioning
demand showed lagging positions (Fig. 2). Sim-
ilarly, for cognitive measures, short-term, marked
clinical deterioration in mild AD was found to be
preceded by a change in tests, such as the TMT-
A, which mainly requires executive functioning and
cognitive processing speed [21, 37]. In fact, these
cognitive domains are involved in many higher-order
processes, which reflect general cognitive integrity
[21], and could explain their early vulnerability to
change before short-term marked clinical deteriora-
tion. Previous stepwise logistic models with mild AD
patients showed that the TMT-A was able to best
discriminate faster from slower progressors, with an
overall accuracy of 68% [21]. Furthermore, multi-
variate analyses with cognitively healthy, MCI, and
AD individuals revealed the TMT-A to be a signifi-
cant predictor of daily functioning [38]. In the present
study, the MMSE score was observed to change early
in short-term, marked disease progression. Consider-
ing its cost-effectiveness and sensitivity, this global
cognitive functioning measure serves as one of the
most effective instruments for monitoring patients
with AD over time [1, 9, 10]. Our results also support
previous reports that changes in the WMS-R delayed
logical memory [31], visuospatial construction [39]
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and semantic fluency [40] scores are suggestive of
disease progression in mild AD.
The similar dynamic of change reflected in both
lead-lag subanalyses (Supplementary Figures 1 and
2), in conjunction with the statistical significance of
the entire analyses robustly supported by bootstrap-
ping with 1000 replicates, added internal validity to
the study and suggested the lack of randomness of
the results. Moreover, in further analyses, lead-lag
analysis was performed using both slow and moder-
ate progressors (Supplementary Figure 3). Although
the B-ADL (LEAD) was preceded by the MMSE,
TMT-A, and WMS-R delayed logical memory, this
composite score showed a leading position and a
high and positive median lead-lag coefficient, sup-
porting its vulnerability to disease progression in
mild AD.
In addition to these findings, we present a new
approach capable of analyzing disease progres-
sion in AD from another perspective, which could
complement classical methods primarily based on
predictions. Furthermore, since slight changes in
functional and cognitive measures occur within the
Alzheimer’s continuum before values considered
severe or very severe are attained, our temporal anal-
ysis of change may help detect individuals at risk of
marked clinical deterioration in the short-term at an
even earlier stage. Of note, none of the study partic-
ipants demonstrated an improvement in any variable
over time. Therefore, in the current study, change
refers to decline or clinical deterioration. Despite
exhibiting several similarities with moderate AD pro-
gressors, slow AD progressors showed a different
pattern of change in cognitive and functional vari-
ables, as revealed by supplementary lead-lag analyses
(Supplementary Figure 4).
Several limitations must be considered when inter-
preting the findings of this study. First, transforming
the change within variables and participants over time
into a rank-order classification of change was nec-
essary. Accordingly, we performed cross-correlation
analyses on an ordinal scale. Therefore, informa-
tion related to questions on the differential effects of
the raw score magnitude of change or the severity
of the deficits is lacking. Conversely, this trans-
formation reduced the information within the data
to only the most necessary. Despite this limitation,
bootstrap estimates with 1000 replications added
internal validity to our lead-lag analyses. Second,
the retrospective selection of moderate decliners was
most likely biased. The demographic and neuropsy-
chological differences between slow and moderate
progressors at baseline (Table 1 and Supplementary
Table 1) support this assumption. Moreover, we sub-
divided the AD collective by change in CDR-SOB,
concurrently applying this variable in lead-lag analy-
ses. This enable exploration of whether the identified
variables preceding short-term marked clinical dete-
rioration in mild AD could be implemented after
corroboration in an independent data set as poten-
tial predictors of pronounced disease progression in
further analyses. Third, we compared different lead-
lag analyses and indirectly rank-ordered changes in
functional and cognitive variables in a general clas-
sification. Since a collective comparison in a general
lead-lag analysis was not possible due to methodolog-
ical issues, the conclusions of the inferred ranking
are hypothetical. Fourth, although such measures fall
far short of the objective of our preliminary analysis
and can be verified in further studies, the 10 B-ADL
(LEAD) items were not utilized in an independent
data set. Furthermore, confirmatory factor analysis
was not performed reliably to examine whether the
two-domain structure by Reppermund and colleagues
[15, 16] was present in the current study. Fifth, as
the TMT-B was not included in further analyses due
to methodological issues, we could not analyze the
TMT B-A time or TMT B/A ratio, which provides
a relatively pure indicator of executive control [41].
However, we have used several cognitive variables
involving executive functions to a greater or lesser
extent. Sixth, only data from baseline and follow-
ups were collected. Although a higher number of
longitudinal evaluations would have improved the
temporal order analysis of our variables, the present
study reflects the clinical setting. Seventh, regarding
functionality, informants vary in their actual con-
tact with the participants and in their capability to
provide valid information. Therefore, we could not
establish the validity of the informants’ reports [15].
However, as all intra-individual analyses were per-
formed with the same informants at all visits, the
possible effect of individual variability is minimized.
Eighth, three baseline scores were found to signifi-
cantly differ between our study sample and the DAP
study population (Supplementary Table 1). However,
these were only of minor relevance for the lead-lag
analyses, which was conducted on within subject
data. Furthermore, these differences were presum-
ably due to our exclusion criteria concerning missing
data and/or follow-up assessments. We hypothesize
that the AD patients from the DAP study who did not
meet our inclusion criteria demonstrated a lower per-
formance at baseline. The exclusion of these patients
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likely resulted in a slight improvement of the three
baseline scores.
In conclusion, short-term clinical deterioration
in mild AD is initially preceded by changes (i.e.,
decline) in a well-defined set of activities of daily
living (ADL) and not in classical cognitive measures.
As ADL are sustained by multiple cognitive domains,
we hypothesize that these activities are more vulner-
able to imminent marked clinical deterioration than
classical cognitive measures. The results of this study
add evidence to the importance of analyzing longi-
tudinal changes in functional abilities as a reliable
measure to detect short-term clinical deterioration in
mild AD. Changes in the TMT-A and MMSE should
also be interpreted as a marker of short-term, pro-
nounced clinical deterioration. Implementation of the
identified items and tests might enable a delay in
the progression of the dependence stage by enforc-
ing clinical and psychosocial interventions far in
advance. Further research employing the outlined
methodology and longer longitudinal designs with
cognitively intact individuals is required to assess the
temporal order of functional and cognitive change
before MCI and dementia stages.
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